Drug Trial Radar · NCT03895112
MPN-RC 118 AVID200 in Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Feb 15, 2019
Primary completion
May 16, 2022
Study completion May 16, 2022
Sponsor
- Lead sponsor
- John MascarenhasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Formation Biologics; National Cancer Institute (NCI); Myeloproliferative Neoplasm Research Consortium (MPN-RC)
- First posted
- Mar 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.
Conditions
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post ET MF
- Post PV MF
Interventions
AVID200Drug
dose cohorts of 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximally tolerated dose (MTD) of AVID200Time frame: After 6 cycles (Each cycle is 21 days)
- Number of patients with response eligibility for Phase 1bTime frame: After 6 cycles
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.